LQDA

LiquidiaF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

earnings

Source

External coverage

Decided

2026-10-01

Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat

Liquidia’s Q2 report showed YUTREPIA net product sales of $170.4 million, up 31% sequentially, supporting the artifact’s positive demand-growth read-through. [Company release](https://www.liquidia.com/news-releases/news-release-details/liquidia-corporation-reports-second-quarter-2026-financial)

View event details1 more curated

Sentiment decomposition

-0.8

30-day score

Company-55%

Macro-30%

Pulse-15%

Weekly research-10-day

Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.

Recent headlines

No supplemental ticker headlines stored yet

We are still collecting relevant articles for LQDA. Curated events highlight the most material developments impacting this ticker right now.

Check curated events Open full news archive

As of 2026-10-01 • Updated scheduledSource: News desk